PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Increasing Awareness and Improved Drug Options Hold Key to Future of European Endometriosis Therapeutics Market - New analysis from Frost & Sullivan, European Endometriosis Therapeutics Market, finds that this market was valued at $365.0 million in 2006 and estimates this to reach $511.6 million in 2013
Increasing Awareness and Improved Drug Options Hold Key to Future of European Endometriosis Therapeutics Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/07/18 - New analysis from Frost & Sullivan, European Endometriosis Therapeutics Market, finds that this market was valued at $365.0 million in 2006 and estimates this to reach $511.6 million in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The European endometriosis therapeutics market will experience sustained growth in the coming years.Rising awareness about the condition coupled with the anticipated launch of improved products will be the major driving forces in market expansion.

New analysis from Frost & Sullivan (pharma.frost.com), European Endometriosis Therapeutics Market, finds that this market was valued at $365.0 million in 2006 and estimates this to reach $511.6 million in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the European Endometriosis Therapeutics Market, send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore@[.]frost.com with your full name, company name, title, telephone number, email address, city, state and country. We will send you the
information through email upon receipt of the above information.

"With a large untreated population, endometriosis remains a considerably underdeveloped market," says Frost & Sullivan Research Analyst Vaibhav Sarvesh. "However, patient awareness about the condition has been increasing, setting the stage for enhanced market penetration."

The projected introduction of novel products with better side effects together with changing raising awareness will help increase adoption levels of endometriosis therapeutics across Europe.
"GnRH Antagonist and progestins with longer treatment periods will be the most important treatment options that will support market expansion," notes Mr. Sarvesh. "Heightened awareness due to information dissemination campaigns, paralleled by the availability of products with enhanced safety profiles will positively impact market growth."

The current lack of efficient and non-invasive diagnostic procedures as well as the negative side effects of existing therapeutics is restraining the market from growing at its real potential. An aging population and restrictive reimbursement policies are further impeding market growth. "Laparoscopy is considered the gold standard for the diagnosis of endometriosis, but this procedure is invasive and costly," adds Mr. Sarvesh. "No new procedures are expected to be launched in the near future, thereby will continue to hinder market growth."

At the same time, the side effect of current treatment options, particularly the effect of some of the drugs on bone density, will pose a major challenge to market expansion until new treatments are introduced.
Considering the large population of untreated patients, increasing awareness will be the key to market growth. Promoting knowledge about the disease coupled with the launch of drugs with fewer side effects will be critical to sustaining market development. Although antagonists are expected to drive the market in the future, success also awaits any innovative therapeutic approach such as the use of progestin modulators.

European Endometriosis Therapeutics Market is part of the Pharmaceutical & Biotechnology Growth Partnership Service, which also includes research in the following markets: European Urinary Incontinence Therapeutics Market, European Blockbusters coming off patent - Opportunities for Generics, and European Osteoarthritis Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Increasing Awareness and Improved Drug Options Hold Key to Future of European Endometriosis Therapeutics Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Radhika Menon Theodore 
rmtheodore@[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)